Cutaan plaveiselcel- of endometriumcarcinoom, fase II, favezelimab-pembrolizumab
Ovariumcarcinoom, fase II, BRCAwt, UV1-olaparib-durvalumab
Ovariumcarcinoom, peritoneale kanker, fase I/II, hoog CA-125, cemiplimab and MUC16-antibody
Solide tumoren, fase I, MET, MET kinase inhibitor
Epitheliaal ovariumcarcinoom, fase I/II, dendritische cel vaccinatie (XP-DC)
Solide tumoren, fase I, 2e lijn, selectieve WEE1 remmer (+carboplatine)
Solide tumoren, fase I, NRG1 fusiegen, antibody HER2/3
Solide tumoren, ‘actionable’ moleculaire target
Solide tumoren, EMA geregistreerde middelen
